14/12/2024: D23 Announces The Sale Of Volpara (VHT.ASX) To Lunit In Korea For A$296m

3 Minute Read

“14/12/2024: D23 Announces the Sale of Volpara (VHT.ASX) to Lunit in Korea for A$296m”

For the text below it can say “D23 was the exclusive financial advisor to Volpara.
After running a comprehensive global sales process involving Tier 1 Private Equity buyers of Software companies, Volpara announced that it has entered into a Scheme Implementation Agreement with Lunit, Inc. under which Lunit has agreed to acquire all of Volpara’s shares at a price of A$1.15 per share in cash by a scheme of arrangement under New Zealand law.

The proposed consideration of A$1.15 per share in cash represents:

55.4% premium to Volpara’s one month volume weighted average price (“VWAP”)
up to 13 December 2023 of A$0.74 per share;
59.7% premium to Volpara’s three-month volume weighted average price
(“VWAP”) up to 13 December 2023 of A$0.72 per share;
An implied equity value of A$296 million;
An enterprise value to FY24 revenue multiple of 7.5x”

14/12/2024: D23 Announces The Sale Of Volpara (VHT.ASX) To Lunit In Korea For A$296m

D23 was the exclusive financial advisor to Volpara.

13/3/2024: Volpara Releases Scheme Implementation Booklet and Sets Shareholder Vote for April 12th 2024

In Relation To The Proposed Acquisition Of All Of The Fully Paid Ordinary Shares In Volpara Health Technologies......

30/11/2023: D23 Hires Technology Banker Vasili Hatzis from Goldman Sachs with Extensive USA Technology Banking Experience

Wellington, NZ, 14 December 2023: Volpara Health Technologies Limited (“Volpara”, “The Group,” Or “The...

Careers with D23Capital advisory

We are always looking for dedicated and passionate professionals to join the D23Capital Advisory team. If you have financial advisory skills or business expertise, we want to hear from you.